Mr Kutay is chief executive officer of Novo Holdings A/S, Denmark.
Mr Kutay is member of the board of Novozymes A/S, Denmark, and
of the Life Sciences Advisory Board of Gimv NV, Belgium.
From 2009 to 2016 Kasim Kutay was managing director, co-head of
Europe and member of the Global Management Committee of Moelis &
Co., UK. From 2007 to 2009 Mr Kutay was managing director and head of
Financial Solutions Group of SUN Group, UK. From 1989 to 2007 Mr Kutay
held a number of positions at Morgan Stanley, UK, including chair of
the European Healthcare Group. Mr Kutay was member of the Board of
Trustees of Northwick Park Institute for Medical Research, UK, from
2005 to 2016. Mr Kutay was member of the Board of Governors from 2006
to 2011 and the Investment Committee from 2011 to 2016 of the School
of Oriental and African Studies (SOAS), UK.
Mr Kutay was first elected to the Board of Novo Nordisk A/S in March
2017 and has most recently been re-elected in March 2020. His term as
a board member expires in March 2021.
In March 2020, the Board of Directors of Novo Nordisk A/S assessed
that Mr Kutay is not regarded as an independent board member as
defined in Section 3.2.1 of the Danish Recommendations on Corporate
Governance designated by Nasdaq Copenhagen due to Mr Kutay being the
chief executive officer of Novo Holdings A/S.
Mr Kutay became a member of the Nomination Committee at Novo
Nordisk A/S in March 2017 and Mr Kutay became member of the Research
& Development Committee at Novo Nordisk A/S in March 2020.
In January 2020, the Board of Directors assessed that the special
competences possessed by Mr Kutay that are important for the
performance of his duties are his extensive experience as financial
advisor to the pharmaceutical, biotechnology and medical device
industries. Further, Mr Kutay has advised healthcare companies on an
international basis including companies based in Europe, the USA,
Japan and India.
Mr Kutay is a UK national, born May 1965.